Management of Non-Pain Conditions 3

1. Which of the following hospice (respective diagnosis listed) patients is most likely closest to death?
2. A hospice QAPI (quality assurance and performance improvement) program should track all of the following data except:
3. Methadone would be a reasonable choice for analgesia in all of the following except?
4. All of the following patients are hospice appropriate except:
5. Which of the following is true regarding ketamine?
6. Which of the following is not true regarding NSAIDs?
7. Which of the following is the most reasonable treatment for severe dyspnea in a patient with end-stage COPD, DNR/DNI, who desires comfort only and is opioid naïve?
8. 84-year-old male with hospice diagnosis of end-stage COPD, PPS 30, with comorbid type 2 DM and diabetic peripheral neuropathy utilizing minimal oral opiates presents with constipation, nausea, and vomiting. Which is the most optimal antiemetic?
9. 49-year-old female with stage 4 breast cancer and insomnia, depression with decreased oral intake, and PPS 50. Which of the following is the best choice of therapy?
10. Which of the following opioids is most likely to cause myoclonus?
11. Buprenorphine is so potent because it is a pure opioid agonist.
12. Buprenorphine is available transdermally and sublingually.
13. Buprenorphine is available intravenously.
14. In hospital palliative care, services always lead to increased hospice utilization in their communities.
15. Supportive care encompasses both hospice and palliative services.
16. Palliative care should be focused only on patient and family goals of care.
17. Aprepitant (substance P inhibitor) has been shown to be an effective analgesic and antiemetic.
18. Olanzapine can be effective as an antiemetic as well as an antipsychotic.
19. Direct thrombin inhibitors are safe in end-stage renal disease, unlike low molecular weight heparinoids.
20. The benefits for atypical antipsychotic use in Alzheimer’s patients with agitation clearly outweigh their risks.